**SUPPLEMENTARY TABLES**

**Supplementary Table S1. The pharmacokinetic profile of bexmarilimab.** Bexmarilimab was administered as a single intravenous dose to cynomolgus monkeys (n(male)=3/dosing group; n(female)=3/dosing group).

|  |  |
| --- | --- |
|   | **Pharmacokinetic parameter (mean, CV(%))**  |
|   | **Dose** **(mg/kg)**  | **C0** **(μg/mL)**  | **AUC∞** **(hr•μg/mL)**  | **T1/2,z** **(h)**  | **CL** **(mL/h/kg)**  | **Vss** **(mL/kg)**  |
| Males  | 3  | 68.9 (9.33)  | 732 (14.6)  | 12.5 (49.2)  | 4.16 (15.8)  | 28.7 (7.39)  |
|   | 30  | 721 (7.86)  | 23,500 (6.22)  | 10.7 (41.9)  | 1.28 (6.19)  | 40.4 (10.9)  |
|   | 100  | 2850 (12.0)  | 154,000 (14.2)  | 25.1 (24.9)  | 0.657 (13.3)  | 37.7 (2.81)  |
|   |   |   |   |   |   |   |
| Females  | 3  | 65.2 (11.8)  | 624 (13.8)  | 24.3 (26.2)  | 4.87 (13.8)  | 31.0 (8.77)  |
|   | 30  | 741 (15.0)  | 17,900 (13.3)  | 16.9 (67.6)  | 1.70 (12.3)  | 37.2 (1.44)  |
|   | 100  | 2660 (8.25)  | 134,000 (15.4)  | 22.8 (34.7)  | 0.757 (14.1)  | 38.8 (11.6)  |

C0, back extrapolated concentration at time zero; AUC∞, area under the curve extrapolated to infinity; T1/2,z, apparent terminal half-life; CL, total clearance; Vss, steady-state volume of distribution.